• Cornerstone Pharmaceuticals Inc., of Cranbury, N.J., started a Phase II trial with CPI-613, its lead altered energy metabolism-directed drug candidate. The pilot study, sponsored by the Comprehensive Cancer Center of Wake Forest Baptist Medical Center, will evaluate the overall response rate for CPI-613 in patients with myelodysplastic syndrome who have been unresponsive to previous therapies. Secondary endpoints include overall survival, progression-free survival, safety and transfusion frequency.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST